LenioBio develops ALiCE, a cell-free protein expression and manufacturing platform designed to enable discovery, development and large-scale production of proteins without the limitations of living cells. The company intends to use the new funding to accelerate R&D on ALiCE, improve processes for large-scale manufacturing, and map various market opportunities. LenioBio is led by CEO Dr. Remberto Martis and has strengthened its Non-executive Board with new members including Thomas Harding, Leopoldo Zambeletti and Karen Fallen. The company was established as a legal entity in Germany in September 2016 and operates offices in Dusseldorf with R&D and production labs in Aachen. Its recent financing activity (a Series A extension) indicates ongoing investor support for its technology and scale-up plans.

Total raised

$13M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022